Literature DB >> 8578018

Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease.

S Kusano1, J Kadota, S Kohno, K Iida, K Kawakami, T Morikawa, K Hara.   

Abstract

To evaluate the effects of roxithromycin in patients with chronic lower respiratory tract disease including diffuse panbronchiolitis, we studied lymphocyte function-associated antigen-1 (LFA-1) and Mac-1, neutrophil adhesion molecules, using peripheral neutrophils from healthy volunteers and from patients with chronic lower respiratory tract disease. The number of Mac-1 expressed on neutrophils of the patients was significantly greater (0.68 +/- 0.16) than in the healthy subjects (0.45 +/- 0.14), while the number of LFA-1 expressed on neutrophils of the patients was nearly similar to that in the healthy volunteers (0.95 +/- 0.10 vs 0.89 +/- 0.11). The neutrophil numbers in bronchoalveolar lavage fluid and the number of Mac-1 expressed on peripheral neutrophils significantly decreased in all patients who responded clinically to a low dose of roxithromycin for a long period of time (56.0 +/- 25.2 vs. 22.7 +/- 19.7%, p < 0.05 and 0.70 +/- 0.16 vs. 0.59 +/- 0.08, p < 0.05, respectively), whereas roxithromycin had no effect on the quantitative expression of LFA-1 (0.96 +/- 0.14 to 1.00 +/- 0.09, not significant) in all responders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578018     DOI: 10.1159/000196450

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

1.  Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis.

Authors:  K Iida; J Kadota; K Kawakami; Y Matsubara; R Shirai; S Kohno
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

Review 2.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells.

Authors:  J Yatsunami; N Tsuruta; Y Fukuno; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

4.  Short-term roxithromycin treatment attenuates airway inflammation via MAPK/NF-κB activation in a mouse model of allergic asthma.

Authors:  Xinxin Ci; Xiao Chu; Xue Xu; Hongyu Li; Xuming Deng
Journal:  Inflamm Res       Date:  2012-04-06       Impact factor: 4.575

5.  Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro.

Authors:  S Kawasaki; H Takizawa; T Ohtoshi; N Takeuchi; T Kohyama; H Nakamura; T Kasama; K Kobayashi; K Nakahara; Y Morita; K Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Azithromycin treatment increases survival of high-risk corneal allotransplants.

Authors:  Carlos A Medina; Alexander M Rowe; Hongmin Yun; Jared E Knickelbein; Kira L Lathrop; Robert L Hendricks
Journal:  Cornea       Date:  2013-05       Impact factor: 2.651

7.  Immunomodulation of endothelial cells induced by macrolide therapy in a model of septic stimulation.

Authors:  Stéphanie Pons; Eden Arrii; Marine Arnaud; Maud Loiselle; Juliette Ferry; Manel Nouacer; Julien Lion; Shannon Cohen; Nuala Mooney; Lara Zafrani
Journal:  Immun Inflamm Dis       Date:  2021-10-12

Review 8.  Macrolides: From Toxins to Therapeutics.

Authors:  Kiersten D Lenz; Katja E Klosterman; Harshini Mukundan; Jessica Z Kubicek-Sutherland
Journal:  Toxins (Basel)       Date:  2021-05-12       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.